Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

The purpose of this study was to estimate in all randomised trials the relative risk of overall response rate (ORR), clinical benefit (CB), time to progression (TTP), overall survival (OS), and toxicity of aromatase inhibitors (AI), compared with tamoxifen (Tam) as first-line endocrine therapy in po...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Ferretti, G, Bria, E, Giannarelli, D, Felici, A, Papaldo, P, Fabi, A, Di Cosimo, S, Ruggeri, E M, Milella, M, Ciccarese, M, Cecere, F L, Gelibter, A, Nuzzo, C, Cognetti, F, Terzoli, E, Carlini, P
التنسيق: Artigo
اللغة:Inglês
منشور في: Nature Publishing Group 2006
الموضوعات:
Clinical Study
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361349/
https://ncbi.nlm.nih.gov/pubmed/16736002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603194
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة